Robyns Tomas, Nuyens Dieter, Vandenberk Bert, Kuiperi Cuno, Corveleyn Anniek, Breckpot Jeroen, Garweg Christophe, Ector Joris, Willems Rik
Department of Cardiovascular Diseases, University Hospitals Leuven, Leuven, Belgium.
Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium.
Ann Noninvasive Electrocardiol. 2018 Sep;23(5):e12548. doi: 10.1111/anec.12548. Epub 2018 Apr 30.
Loss-of-function (LoF) mutations in the SCN5A gene cause multiple phenotypes including Brugada Syndrome (BrS) and a diffuse cardiac conduction defect. Markers of increased risk for sudden cardiac death (SCD) in LoF SCN5A mutation carriers are ill defined. We hypothesized that late potentials and fragmented QRS would be more prevalent in SCN5A mutation carriers compared to SCN5A-negative BrS patients and evaluated risk markers for SCD in SCN5A mutation carriers.
We included all SCN5A loss-of-function mutation carriers and SCN5A-negative BrS patients from our center. A combined arrhythmic endpoint was defined as appropriate ICD shock or SCD.
Late potentials were more prevalent in 79 SCN5A mutation carriers compared to 39 SCN5A-negative BrS patients (66% versus 44%, p = .021), while there was no difference in the prevalence of fragmented QRS. PR interval prolongation was the only parameter that predicted the presence of a SCN5A mutation in BrS (OR 1.08; p < .001). Four SCN5A mutation carriers, of whom three did not have a diagnostic type 1 ECG either spontaneously or after provocation with a sodium channel blocker, reached the combined arrhythmic endpoint during a follow-up of 44 ± 52 months resulting in an annual incidence rate of 1.37%.
LP were more frequently observed in SCN5A mutation carriers, while fQRS was not. In SCN5A mutation carriers, the annual incidence rate of SCD was non-negligible, even in the absence of a spontaneous or induced type 1 ECG. Therefore, proper follow-up of SCN5A mutation carriers without Brugada syndrome phenotype is warranted.
SCN5A基因功能丧失(LoF)突变会导致多种表型,包括 Brugada 综合征(BrS)和弥漫性心脏传导缺陷。LoF SCN5A 突变携带者发生心源性猝死(SCD)风险增加的标志物尚不明确。我们假设与 SCN5A 阴性的 BrS 患者相比,SCN5A 突变携带者中晚期电位和碎裂 QRS 更为普遍,并评估了 SCN5A 突变携带者中 SCD 的风险标志物。
我们纳入了来自本中心的所有 SCN5A 功能丧失突变携带者和 SCN5A 阴性的 BrS 患者。将适当的植入式心律转复除颤器(ICD)电击或 SCD 定义为联合心律失常终点。
与 39 例 SCN5A 阴性的 BrS 患者相比,79 例 SCN5A 突变携带者中晚期电位更为普遍(66% 对 44%,p = 0.021),而碎裂 QRS 的患病率无差异。PR 间期延长是预测 BrS 中 SCN5A 突变存在的唯一参数(比值比 1.08;p < 0.001)。4 例 SCN5A 突变携带者在 44±52 个月的随访期间达到联合心律失常终点,其中 3 例无论是自发还是在使用钠通道阻滞剂激发后均无诊断性 1 型心电图,年发病率为 1.37%。
在 SCN5A 突变携带者中更频繁地观察到晚期电位,而碎裂 QRS 则不然。在 SCN5A 突变携带者中,即使没有自发或诱发的 1 型心电图,SCD 的年发病率也不可忽视。因此,对无 Brugada 综合征表型的 SCN5A 突变携带者进行适当随访是必要的。